Information Provided By: 
Fly News Breaks for October 10, 2016
TSRO
Oct 10, 2016 | 09:24 EDT
Credit Suisse analyst Alethia Young raised TESARO's price target to $122 from $90 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The analyst thinks niraparib has broad effects across the 2nd line ovarian population and would expect the label is broad. Young has an Outperform ratting n TESARO shares.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
